Literature DB >> 18498083

Introducing metallocene into a triazole peptide conjugate reduces its off-rate and enhances its affinity and antiviral potency for HIV-1 gp120.

Hosahudya Gopi1, Simon Cocklin, Vanessa Pirrone, Karyn McFadden, Ferit Tuzer, Isaac Zentner, Sandya Ajith, Sabine Baxter, Navneet Jawanda, Fred C Krebs, Irwin M Chaiken.   

Abstract

In this work, we identified a high affinity and potency metallocene-containing triazole peptide conjugate that suppresses the interactions of HIV-1 envelope gp120 at both its CD4 and co-receptor binding sites. The ferrocene-peptide conjugate, HNG-156, was formed by an on-resin copper-catalysed [2+3] cycloaddition reaction. Surface plasmon resonance interaction analysis revealed that, compared to a previously reported phenyl-containing triazole conjugate HNG-105 (105), peptide 156 had a higher direct binding affinity for several subtypes of HIV-1 gp120 due mainly to the decreased dissociation rate of the conjugate-gp120 complex. The ferrocene triazole conjugate bound to gp120 of both clade A (92UG037-08) and clade B (YU-2 and SF162) virus subtypes with nanomolar KD in direct binding and inhibited the binding of gp120 to soluble CD4 and to antibodies that bind to HIV-1YU-2 gp120 at both the CD4 binding site and CD4-induced binding sites. HNG-156 showed a close-to nanomolar IC50 for inhibiting cell infection by HIV-1BaL whole virus. The dual receptor site antagonist activity and potency of HNG-156 make it a promising viral envelope inhibitor lead for developing anti-HIV-1 treatments. Copyright (c) 2008 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18498083      PMCID: PMC3652662          DOI: 10.1002/jmr.892

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  30 in total

1.  Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library.

Authors:  Mei-Yun Zhang; Yuuei Shu; Sanjay Phogat; Xiaodong Xiao; Fatim Cham; Peter Bouma; Anil Choudhary; Yan-Ru Feng; Inaki Sanz; Susanna Rybak; Christopher C Broder; Gerald V Quinnan; Thomas Evans; Dimiter S Dimitrov
Journal:  J Immunol Methods       Date:  2003-12       Impact factor: 2.303

2.  A small molecule HIV-1 inhibitor that targets the HIV-1 envelope and inhibits CD4 receptor binding.

Authors:  Pin-Fang Lin; Wade Blair; Tao Wang; Timothy Spicer; Qi Guo; Nannan Zhou; Yi-Fei Gong; H-G Heidi Wang; Ronald Rose; Gregory Yamanaka; Brett Robinson; Chang-Ben Li; Robert Fridell; Carol Deminie; Gwendeline Demers; Zheng Yang; Lisa Zadjura; Nicholas Meanwell; Richard Colonno
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-20       Impact factor: 11.205

3.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

Authors:  Vsevolod V Rostovtsev; Luke G Green; Valery V Fokin; K Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2002-07-15       Impact factor: 15.336

4.  The theta-defensin, retrocyclin, inhibits HIV-1 entry.

Authors:  Carsten Münk; Ge Wei; Otto O Yang; Alan J Waring; Wei Wang; Teresa Hong; Robert I Lehrer; Nathaniel R Landau; Alexander M Cole
Journal:  AIDS Res Hum Retroviruses       Date:  2003-10       Impact factor: 2.205

5.  Mode of action for linear peptide inhibitors of HIV-1 gp120 interactions.

Authors:  Alyssa C Biorn; Simon Cocklin; Navid Madani; Zhihai Si; Tijana Ivanovic; James Samanen; Donald I Van Ryk; Ralph Pantophlet; Dennis R Burton; Ernesto Freire; Joseph Sodroski; Irwin M Chaiken
Journal:  Biochemistry       Date:  2004-02-24       Impact factor: 3.162

6.  Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.

Authors:  C Vita; E Drakopoulou; J Vizzavona; S Rochette; L Martin; A Ménez; C Roumestand; Y S Yang; L Ylisastigui; A Benjouad; J C Gluckman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-09       Impact factor: 11.205

7.  HIV-1 reverse transcription. A termination step at the center of the genome.

Authors:  P Charneau; G Mirambeau; P Roux; S Paulous; H Buc; F Clavel
Journal:  J Mol Biol       Date:  1994-09-02       Impact factor: 5.469

8.  Beta-turn Phe in HIV-1 Env binding site of CD4 and CD4 mimetic miniprotein enhances Env binding affinity but is not required for activation of co-receptor/17b site.

Authors:  Cynthia S Dowd; Stephanie Leavitt; Gregory Babcock; Alexis P Godillot; Don Van Ryk; Gabriela A Canziani; Joseph Sodroski; Ernesto Freire; Irwin M Chaiken
Journal:  Biochemistry       Date:  2002-06-04       Impact factor: 3.162

9.  Inactivation of human immunodeficiency virus type 1 by nonoxynol-9, C31G, or an alkyl sulfate, sodium dodecyl sulfate.

Authors:  F C Krebs; S R Miller; D Malamud; M K Howett; B Wigdahl
Journal:  Antiviral Res       Date:  1999-10       Impact factor: 5.970

10.  The entry of entry inhibitors: a fusion of science and medicine.

Authors:  John P Moore; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-05       Impact factor: 11.205

View more
  20 in total

1.  Chemical optimization of macrocyclic HIV-1 inactivators for improving potency and increasing the structural diversity at the triazole ring.

Authors:  Adel A Rashad; Kriti Acharya; Ann Haftl; Rachna Aneja; Alexej Dick; Andrew P Holmes; Irwin Chaiken
Journal:  Org Biomol Chem       Date:  2017-09-26       Impact factor: 3.876

2.  The active core in a triazole peptide dual-site antagonist of HIV-1 gp120.

Authors:  Muddegowda Umashankara; Karyn McFadden; Isaac Zentner; Arne Schön; Srivats Rajagopal; Ferit Tuzer; Syna A Kuriakose; Mark Contarino; Judith Lalonde; Ernesto Freire; Irwin Chaiken
Journal:  ChemMedChem       Date:  2010-11-08       Impact factor: 3.466

3.  Impact of HIV-1 Membrane Cholesterol on Cell-Independent Lytic Inactivation and Cellular Infectivity.

Authors:  Ramalingam Venkat Kalyana Sundaram; Huiyuan Li; Lauren Bailey; Adel A Rashad; Rachna Aneja; Karl Weiss; James Huynh; Arangaserry Rosemary Bastian; Elisabeth Papazoglou; Cameron Abrams; Steven Wrenn; Irwin Chaiken
Journal:  Biochemistry       Date:  2016-01-14       Impact factor: 3.162

4.  Non-natural peptide triazole antagonists of HIV-1 envelope gp120.

Authors:  Kantharaju Kamanna; Rachna Aneja; Caitlin Duffy; Pamela Kubinski; Diogo Rodrigo Moreira; Lauren D Bailey; Karyn McFadden; Arne Schön; Andrew Holmes; Ferit Tuzer; Mark Contarino; Ernesto Freire; Irwin M Chaiken
Journal:  ChemMedChem       Date:  2012-12-13       Impact factor: 3.466

5.  Cell-free HIV-1 virucidal action by modified peptide triazole inhibitors of Env gp120.

Authors:  Arangassery R Bastian; Karyn McFadden; Caitlin Duffy; Srivats Rajagopal; Mark R Contarino; Elisabeth Papazoglou; Irwin Chaiken
Journal:  ChemMedChem       Date:  2011-06-28       Impact factor: 3.466

6.  Short Communication: Inhibition of DC-SIGN-Mediated HIV-1 Infection by Complementary Actions of Dendritic Cell Receptor Antagonists and Env-Targeting Virus Inactivators.

Authors:  Sergey Pustylnikov; Rajnish S Dave; Zafar K Khan; Vanessa Porkolab; Adel A Rashad; Matthew Hutchinson; Frank Fieschi; Irwin Chaiken; Pooja Jain
Journal:  AIDS Res Hum Retroviruses       Date:  2015-09-18       Impact factor: 2.205

7.  Use of the quartz crystal microbalance to monitor ligand-induced conformational rearrangements in HIV-1 envelope protein gp120.

Authors:  Hyun-Su Lee; Mark Contarino; M Umashankara; Arne Schön; Ernesto Freire; Amos B Smith; Irwin M Chaiken; Lynn S Penn
Journal:  Anal Bioanal Chem       Date:  2009-12-17       Impact factor: 4.142

8.  A model of peptide triazole entry inhibitor binding to HIV-1 gp120 and the mechanism of bridging sheet disruption.

Authors:  Ali Emileh; Ferit Tuzer; Herman Yeh; Muddegowda Umashankara; Diogo R M Moreira; Judith M Lalonde; Carole A Bewley; Cameron F Abrams; Irwin M Chaiken
Journal:  Biochemistry       Date:  2013-03-22       Impact factor: 3.162

9.  Peptide triazole inactivators of HIV-1: how do they work and what is their potential?

Authors:  Irwin Chaiken; Adel A Rashad
Journal:  Future Med Chem       Date:  2015-11-24       Impact factor: 3.808

10.  Macrocyclic Envelope Glycoprotein Antagonists that Irreversibly Inactivate HIV-1 before Host Cell Encounter.

Authors:  Adel A Rashad; Ramalingam Venkat Kalyana Sundaram; Rachna Aneja; Caitlin Duffy; Irwin Chaiken
Journal:  J Med Chem       Date:  2015-09-11       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.